Anain Paul M, Anain Joseph M, Tiso Michael, Nader Nader D, Dosluoglu Hasan H
Sisters of Charity Hospital, State University of New York at Buffalo, Buffalo, NY, USA.
J Vasc Surg. 2007 Nov;46(5):898-905. doi: 10.1016/j.jvs.2007.06.037.
Endovascular repair (EVAR) has been increasingly used for ruptured abdominal aortic aneurysms (rAAAs), especially in major academic centers. The goal of this article is to report our results with an EVAR-first approach for rAAA which we adopted in 2001 in our community hospital.
All consecutive patients who underwent attempted repair for rAAA between February 2001 and July 2006 were analyzed. Only patients with computed tomographic or visual verification of extraluminal blood were included.
A total of 40 patients (30 men; mean age, 76.4 +/- 7.2 years; range, 57-89 years) presented with rAAA. Thirty patients underwent attempted EVAR for rAAA, constituting 4.1% of all EVAR cases (n = 738), and 10 patients had attempted open repair. Twenty-one (53%) were transferred from another institution. Computed tomography was performed in 97.5%. On arrival to the emergency department, 43%% were hypotensive (systolic blood pressure <80 mm Hg). Transfemoral balloon occlusion was used in 12 cases (30%; 10 in the EVAR group and 2 in the open group). The length of operation was 128 +/- 35 minutes (range, 77-210 minutes) in EVAR cases. EVAR was completed in 93.3% (iliac anatomy and proximal endoleak caused open conversion in two cases). Out of the 10 open treated cases, 1 was converted to EVAR and survived. The grafts used for EVAR were AneuRx (n = 21), Zenith (n = 5), and Ancure (n = 4), and 97% were bifurcated. Five patients (16.6%) in the EVAR group died within 30 days (four required balloon occlusion). The mean length of stay was 9.1 +/- 6.2 days (range, 4-30 days) in survivors of EVAR. In the EVAR-treated group, two patients died (7 and 9 months; unrelated), and six of the surviving patients (23%) required secondary procedures (five femorofemoral bypasses for limb occlusions and one proximal cuff for a type I endoleak that caused repeat rupture) during a mean follow-up of 13.8 +/- 10.4 months (range, 3-39 months). The mortality rate was 40% (4/10) in patients who underwent open procedures during this period, with an overall mortality rate of 22.5% for all ruptures treated. The difference in 30-day mortality in the EVAR and open groups did not reach statistical significance (17% vs 40%; P = .19). In the entire cohort, hypotension (systolic blood pressure <80 mm Hg) on arrival and loss of consciousness were associated with 30-day mortality. Balloon occlusion was correlated with mortality in the EVAR-treated group (44% vs 4%; P = .019). The multivariate analysis using logistic regression showed that hypotension (odds ratio [OR], 7.4; 95% confidence interval [CI], 1.3-42.0; P = .025), loss of consciousness (OR, 37.5; 95% CI, 3.4-40.8; P = .003), and the need for balloon occlusion (OR, 5.2; 95% CI, 1.8-25.5; P = .042) were correlated with higher perioperative mortality, whereas age greater than 76 years, coronary artery disease, chronic obstructive pulmonary disease, hypertension, diabetes, renal insufficiency, and type of procedure did not.
Our results show that EVAR is feasible with favorable outcomes in patients presenting with rAAA in a busy community hospital. There is a high secondary intervention rate, which can potentially be decreased by ensuring good iliac limb anatomy at the end of the procedure and by a closer follow-up.
血管腔内修复术(EVAR)已越来越多地用于治疗破裂性腹主动脉瘤(rAAA),尤其是在主要学术中心。本文的目的是报告我们自2001年起在社区医院采用EVAR优先治疗rAAA的结果。
分析了2001年2月至2006年7月间所有接受rAAA修复术的连续患者。仅纳入经计算机断层扫描或肉眼证实有腔外血液的患者。
共有40例患者(30例男性;平均年龄76.4±7.2岁;范围57 - 89岁)表现为rAAA。30例患者尝试接受rAAA的EVAR治疗,占所有EVAR病例(n = 738)的4.1%,10例患者尝试接受开放修复。21例(53%)患者从其他机构转诊而来。97.5%的患者进行了计算机断层扫描。到达急诊科时,43%的患者血压过低(收缩压<80 mmHg)。12例患者(30%;EVAR组10例,开放组2例)采用了经股动脉球囊封堵术。EVAR病例的手术时长为128±35分钟(范围77 - 210分钟)。93.3%的EVAR手术成功完成(2例因髂动脉解剖结构和近端内漏转为开放手术)。在10例接受开放治疗的病例中,1例转为EVAR并存活。用于EVAR的移植物有AneuRx(n = 21)、Zenith(n = 5)和Ancure(n = 4),97%为分叉型。EVAR组5例患者(16.6%)在30天内死亡(4例需要球囊封堵)。EVAR幸存者的平均住院时长为9.1±6.2天(范围4 - 30天)。在EVAR治疗组中,2例患者死亡(分别在7个月和9个月;与手术无关),在平均13.8±10.4个月(范围3 - 39个月)的随访期间,6例存活患者(23%)需要二次手术(5例因肢体闭塞行股股旁路移植术,1例因I型内漏导致再次破裂行近端袖带修复术)。在此期间接受开放手术的患者死亡率为40%(4/10),所有接受治疗的破裂患者总体死亡率为22.5%。EVAR组和开放组30天死亡率的差异未达到统计学意义(17%对40%;P = 0.19)。在整个队列中,到达时低血压(收缩压<80 mmHg)和意识丧失与30天死亡率相关。球囊封堵与EVAR治疗组的死亡率相关(44%对4%;P = 0.019)。使用逻辑回归的多变量分析显示,低血压(比值比[OR],7.4;95%置信区间[CI],1.3 - 42.0;P = 0.025)、意识丧失(OR,37.5;95% CI,3.4 - 40.8;P = 0.003)以及球囊封堵的需求(OR,5.2;95% CI,1.8 - 25.5;P = 0.042)与围手术期较高死亡率相关,而年龄大于76岁、冠状动脉疾病、慢性阻塞性肺疾病、高血压、糖尿病、肾功能不全和手术类型则无关。
我们的结果表明,在繁忙的社区医院中,EVAR对rAAA患者是可行的,且效果良好。二次干预率较高,通过在手术结束时确保良好的髂支解剖结构以及更密切的随访,可能会降低这一比率。